title: [Mutation analysis of the HBV reverse transcriptase in nucleos(t)ide-treated patients with chronic HBV infection].
abstract: OBJECTIVE
  To characterize genotypic resistance within HBV RT region in chronic hepatitis B (CHB) patients with nucleos(t)ide analogue (NA) treatment.
  
  
  METHODS
  Serum samples of 229 CHB patients with NA treatment were obtained. Full-length HBV RT sequences were amplified, sequenced and analyzed, on the following NA resistant (NAr) mutations belonging to different NAr pathways.
  
  
  RESULTS
  Among 229 HBV isolates, 14.41% (33/229) and 85.59% (196/229) were genotype B and C, respectively; and the patients with HBV genotype C may be more susceptible to develope resistant mutations than patients with HBV genotype B(chi2 = 2.95, P < 0.05). NAr mutations were detected in 63 CHB patients. Mutations were not found at rtI169, rtT184, rtA194 or rtS202. RtM204 mutations were detected at the highest frequency among 63 mutants (40/63, 63.49%) and found to display 11 combination mutation patterns, in which rtM204I were associated with rtL80I/V and rtL180M, and rtM204V were associated with rtL1l80M, respectively. Conclusions There are complicated mutation patterns in the HBV RT region for chronic hepatitis B (CHB) patients with nucleos(t)ide analogue (NA) treatment. RtM204V/I mutation was the highest.
authors.affiliation: Department of Liver Diseases, Qinhuangdao Third Hospital, China. xiujuanjiao@163.com
authors.forename: Xiu-Juan
authors.initials: XJ
authors.lastname: Jiao
authors.forename: Xun
authors.initials: X
authors.lastname: Peng
authors.forename: Xiu-Min
authors.initials: XM
authors.lastname: Jiao
authors.forename: Jin-Sheng
authors.initials: JS
authors.lastname: Wang
authors.forename: Xie-Wen
authors.initials: XW
authors.lastname: Sun
authors.forename: Pei-Li
authors.initials: PL
authors.lastname: Zhao
authors.forename: Shou-Yun
authors.initials: SY
authors.lastname: Wang
authors.forename: Jia-Qun
authors.initials: JQ
authors.lastname: Liu
authors.forename: Tong
authors.initials: T
authors.lastname: Li
authors.forename: Jing-Xian
authors.initials: JX
authors.lastname: Yang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D006515:Hepatitis B virus / Q000187:drug effects / Q000201:enzymology* / Q000235:genetics; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000187:drug effects*; D009705:Nucleosides / Q000627:therapeutic use*; D009711:Nucleotides / Q000627:therapeutic use*; D012194:RNA-Directed DNA Polymerase / Q000235:genetics* / Q000378:metabolism; D014764:Viral Proteins / Q000235:genetics* / Q000378:metabolism; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D009705:Nucleosides; D009711:Nucleotides; D014764:Viral Proteins; D012194:RNA-Directed DNA Polymerase